CORRECTING and REPLACING Sanguine Meets with FDA To Define PHER-O2 Regulatory Path
PASADENA, Calif., Dec 06, 2006 (BUSINESS WIRE) -- Second graph, first sentence
of release dated Dec. 5, 2006 should read: PIRIBO, a well known BioPharma
Industry analyst, reported that the annual organ and tissue transplantation
market in the U.S. was estimated at $11.7 billion in 2005 and is expected to
rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010
(sted PRIBO, a well known BioPharma Industry analyst, reported that the annual
organ and tissue transplantation market in the U.S. was estimated at $11.7
billion in 2005 and is expected to rise at an average annual growth rate (AAGR)
of 5.2% to $15.1 billion by 2010.)
The corrected release reads:
SANGUINE MEETS WITH FDA TO DEFINE PHER-O2 REGULATORY PATH
Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company
focused on the development of an oxygen-carrying synthetic substitute for human
red blood cells and numerous other areas requiring oxygen profusion, in
collaboration with its FDA testing contractors and development team, met with
the FDA to discuss the Company's regulatory path. The Company believes that its
product, PHER-O2, is appropriately suited for whole organ (pancreas and kidney),
preservation for transplantation.
PIRIBO, a well known BioPharma Industry analyst, reported that the annual organ
and tissue transplantation market in the U.S. was estimated at $11.7 billion in
2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to
$15.1 billion by 2010. The transplantation market was estimated at just under $5
billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector
is small bowel (intestine) transplantation. Kidney and liver transplantation
will account for 78% of the total in 2005. The U.S. tissue transplantation
market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of
5.5%, to $8.9 billion in 2010. A copy of the report may be found at:
www.piribo.com/publications/biotechnology/organ_tissue_
transplantation_alternatives.html (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the extra space
if one exists.)
Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely
excited to have finally met with the FDA related to our testing program. As I
have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell
preservation in treating diabetes (the fastest growing disease in the world) is
particularly attractive because the product is used ex-vivo (outside the body),
which should simplify the regulatory process. We are most interested in
generating a device indication that presumably would be the most expedient route
toward our ability to market PHER-O2. As indicated by numerous BioPharma
sources, the transplantation market is substantially large. Our plan is to use
PHER-O2 in conjunction with other transplantation transport materials to provide
an oxygenated environment to aid in the longevity of whole organs. We look
forward to having our development team continue its work with the FDA to
finalize the most appropriate and direct regulatory path. We feel the meeting
with the FDA was quite successful."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy@allwest.netwww.sanguine-corp.com
Copyright Business Wire 2006
invest at your own risk, based on your own due diligence, at your own risk tolerance
